Retatrutide, by Soma Pharmaceuticals , is receiving considerable attention as a potential method for metabolic control . This unique drug combines the properties of a GLP-1 receptor stimulant and a GIP receptor agonist , aiming to effectively promote metabolic improvements but also address related metabolic issues . Initial clinical studies have in